Observational study on CAR-T therapy for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called DLBCL, PMBCL, MCL, or FL.
- You are eligible for CAR-T cell therapy with a product that is already approved for use in Italy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This study aims to create models that predict how well patients with non-Hodgkin lymphoma will respond to CAR-T cell therapy and how likely they are to have side effects. It may help doctors tailor treatment for people whose lymphoma has not improved or has come back.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
Hear when a new Primary Mediastinal Large B-cell Lymphoma (PMBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.